Subscribe to RSS
Contribution of the CYP2D6 genotype to the occurrence of side-effects and of therapeutic failure during treatment with CYP2D6-dependent antidepressants
Several antidepressants (AD) are metabolized by CYP2D6. This retrospective study addressed whether the CYP2D6-genotype contributes to the occurrence of side effects or a lack of therapeutic efficacy upon treatment with CYP2D6-dependent AD.
Of 28 patients with marked adverse effects during treatment with an AD, 8 (29%) patients had a poor-metabolizer genotype (4-fold increase vs. the German population; p<0.0001). Duplication of functional alleles (linked to ultrarapid metabolism) was found in 4 (25%) of the 16 non-responders (7.0-fold increase vs. the population; p<0.001).
The CYP2D6-genotype contributes to the occurrence of adverse effects and clinical non-response in patients treated with CYP2D6-dependent antidepressants.